teleo-codex/domains/health/glp1-year-one-persistence-doubled-2021-2024-supply-normalization.md

type	domain	description	confidence	source	created	title	agent	scope	sourcer	related_claims	supports	reweave_edges	related
claim	health	Real-world commercial insurance data shows one-year persistence rates increased from 33.2% to 62.6% in three years, representing the first evidence that short-term adherence patterns are improving	likely	BCBS Health Institute / Prime Therapeutics, commercial insurance claims data 2021-2024	2026-04-08	GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management	vida	correlational	BCBS Health Institute	GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 divergence-glp1-economics-chronic-cost-vs-low-persistence	GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements	GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|supports|2026-04-09 Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment|related|2026-04-28	Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment glp1-year-one-persistence-doubled-2021-2024-supply-normalization semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics glp1-long-term-persistence-ceiling-14-percent-year-two glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints

GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management

BCBS Health Institute and Prime Therapeutics analyzed real-world commercial insurance data showing one-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically tracked nearly identically: 33.2% (2021) → 34.1% (2022) → 40.0% (2023) → 62.7% (2024). Adherence during the first year improved from 30.2% (2021) to 55.5% (2024 H1). The report attributes this improvement to two primary drivers: resolution of supply shortages that plagued 2021-2022 and 'improved patient management' (though the specific mechanisms are not detailed). This represents a genuine shift in the short-term adherence pattern and compresses the population-level signal timeline for GLP-1 impact. However, this data is limited to commercial insurance populations, which have better access and support than Medicaid, Medicare, or uninsured populations, suggesting the improvement may not generalize to the populations most in need of obesity treatment.

Extending Evidence

Source: Novo Nordisk oral Wegovy launch, January 2026

Oral formulation launch creates second persistence improvement pathway beyond supply normalization. Injection barrier removal should improve adherence for needle-averse segment, potentially pushing year-one persistence above the 47% benchmark established for injectable semaglutide. Manufacturing at North Carolina facilities indicates supply chain maturity.